EGFR and non-small cell lung carcinoma: For instance, in osimertinib-resistant EGFR-mutant NSCLC, which is reported to undergo a metabolic switch from glycolysis to OXPHOS, phenformin was able to delay the long-term development of osimertinib resistance [51].